ArticleImmunity2020
High Amount of Transcription Factor IRF8 Engages AP1-IRF Composite Elements in Enhancers to Direct Type 1 Conventional Dendritic Cell Identity.
Article in Immunity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 76 citations in OpenAlex.
- PARP1-selective inhibitor DSB1559 demonstrates superior efficacy and antitumor immunity in triple-negative breast cancer.Journal for immunotherapy of cancer · 2026Article
- IL-17D reprograms CD93Cellular & molecular immunology · 2026Article
- Review
- Tumor-induced dendritic cell deregulation perturbs T cell proliferation and predicts clinical outcome in acute lymphoblastic leukemia.Cell reports. Medicine · 2026Article
- Analysis of Allele-Specific Expression Highlights Novel Participants of Empagliflozin-Driven Effects on T2DM-Associated Regulatory Pathways.International journal of molecular sciences · 2026Article
- Early, adjuvant-responsive epigenetic programs in B cells imprint subsequent plasma cell survival and the duration of humoral immunity.bioRxiv : the preprint server for biology · 2025Article
- Rewriting the dendritic cell code in cancer-from subset identity to immunotherapeutic design.FEBS letters · 2025Review
- Cutting Edge: Cooperative interferon regulatory factor network shapes the NK-cell antiviral response.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- C/EBPα activatesScience immunology · 2025Article
- Article
- Modulation of the tumor immune microenvironment by Interferon Regulatory Factor 8 enhances immunotherapy in lung adenocarcinoma.Scientific reports · 2025Article
- Super-enhancers in immune system regulation: mechanisms, pathological reprogramming, and therapeutic opportunities.Frontiers in immunology · 2025Review
- CD11c-Cre driven deletion ofFrontiers in immunology · 2025Article
- Microbiota-derived butyrate inhibits cDC development via HDAC inhibition, diminishing their ability to prime T cells.Mucosal immunology · 2024Article
- Weak enhancer allows autoactivation of Irf8 to control cDC1 versus cDC2 lineage commitment.Nature immunology · 2024Article
- Optimization of the Irf8 +32-kb enhancer disrupts dendritic cell lineage segregation.Nature immunology · 2024Article
- IRF8 deficiency-induced myeloid-derived suppressor cell promote immune evasion in lung adenocarcinoma.Journal of translational medicine · 2024Article
- Quantitative trait loci mapping provides insights into the genetic regulation of dendritic cell numbers in mouse tissues.Cell reports · 2024Article
- Transcription factor C/EBPα is required for the development of Ly6CProceedings of the National Academy of Sciences of the United States of America · 2024Article
- Emerging T cell immunoregulatory mechanisms in multiple sclerosis and Alzheimer's disease.Frontiers in aging neuroscience · 2024Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Development and function of conventional dendritic cell (cDC) subsets, cDC1 and cDC2, depend on transcription factors (TFs) IRF8 and IRF4, respectively. Since IRF8 and IRF4 can each interact with TF BATF3 at AP1-IRF composite elements (AICEs) and with TF PU.1 at Ets-IRF composite elements (EICEs), it is unclear how these factors exert divergent actions. Here, we determined the basis for distinct effects of IRF8 and IRF4 in cDC development. Genes expressed commonly by cDC1 and cDC2 used EICE-dependent enhancers that were redundantly activated by low amounts of either IRF4 or IRF8. By contrast, cDC1-specific genes relied on AICE-dependent enhancers, which required high IRF concentrations, but were activated by either IRF4 or IRF8. IRF8 was specifically required only by a minority of cDC1-specific genes, such as Xcr1, which could distinguish between IRF8 and IRF4 DNA-binding domains. Thus, these results explain how BATF3-dependent Irf8 autoactivation underlies emergence of the cDC1-specific transcriptional program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.